We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Engex, Inc. | AMEX:EGX | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
|
SHARES |
MARKET
VALUE
|
TOTAL |
MARKETABLE SECURITIES:
COMMON STOCK (82%)
|
||||||||||||
Biotechnology (81.9%)
|
||||||||||||
Enzo Biochem, Inc.*
|
1,050,096 shs
|
$ | 4,462,908 | |||||||||
Keryx Biopharmaceuticals, Inc.*
|
31,700 shs
|
$ | 149,941 | |||||||||
MiMedx Group, Inc.*
|
382,342 shs
|
$ | 293,639 | |||||||||
$ | 4,906,488 | |||||||||||
Technology (0.0%)
|
||||||||||||
Silverstar Holdings Ltd. *
|
51,600 shs
|
$ | 516 | |||||||||
$ | 516 | |||||||||||
Gaming Industry (.2%)
|
||||||||||||
American Vantage Companies *
|
474,500 shs
|
$ | 12,147 | |||||||||
$ | 12,147 | |||||||||||
TOTAL INVESTMENT IN MARKETABLE SECURITIES
(COST – $9,001,763)
|
$ | 4,919,151 | ||||||||||
PRIVATE INVESTMENTS* (9.5%)
|
||||||||||||
Lifesync Holdings, Inc. (a)
|
4,675 shs
|
0 | ||||||||||
Corente, Inc. (b)
|
11,793 shs
|
0 | ||||||||||
GFK AG 3
rd
Closing Price Receivable (c)
|
N/A | $ | 172,288 | |||||||||
MRI Interventions, Inc. Common Stock (d)
|
569,684 shs
|
$ | 333,312 | |||||||||
MRI Interventions, Inc. Promissory Note (d)
|
$ | 33,945 | ||||||||||
Mimedx Group, Inc. B1 Warrant *
|
50,000 shs
|
$ | 12,500 | |||||||||
Mimedx Group, Inc. B2 Warrant *
|
25,000 shs
|
$ | 8,875 | |||||||||
Mimedx Group, Inc. B3 Warrant *
|
25,000 shs
|
$ | 8,875 | |||||||||
TOTAL PRIVATE INVESTMENTS
(COST – $2,937,054)
|
$
|
569,795
|
Level 1 –
Quoted
Prices
|
Level 2-
Other
Significant
Observable
Inputs *
|
Level 3-
Significant
Unobservable
Inputs
|
Total Fair
Value at
March 31,
2011
|
|||||||||||||
Marketable Securities:
|
||||||||||||||||
American Vantage Companies
|
$ | 12,147 | -- | $ | 12,147 | |||||||||||
Enzo Biochem, Inc.
|
$ | 4,462,908 | -- | -- | 4,462,908 | |||||||||||
Keryx Biopharmaceuticals, Inc.
|
149,941 | -- | -- | 149,941 | ||||||||||||
MiMedx Group, Inc.
|
-- | 293,639 | -- | 293,639 | ||||||||||||
Silverstar Holdings Ltd
|
516 | -- | 516 | |||||||||||||
Total Investment in Marketable Securities
|
$ | 4,613,365 | $ | 305,786 | $ | -- | $ | 4,919,151 | ||||||||
Private Investments:
|
||||||||||||||||
MiMedx Group, Inc. Warrants Restricted B1**
|
-- | -- | 12,500 | 12,500 | ||||||||||||
MiMedx Group, Inc. Warrants Restricted B2**
|
-- | -- | 8,875 | 8,875 | ||||||||||||
MiMedx Group, Inc. Warrants Restricted B3**
|
-- | -- | 8,875 | 8,875 | ||||||||||||
MRI Interventions, Inc. (formerly, Surgivision, Inc.)
|
-- | -- | 333,312 | 333,312 | ||||||||||||
MRI Interventions, Inc. (formerly, Surgivision, Inc.) Note
|
-- | -- | 33,945 | 33,945 | ||||||||||||
GFK AG 3
rd
Closing Price Receivable
|
-- | -- | 172,288 | 172,288 | ||||||||||||
Total Private Investments
|
$ | -- | $ | -- | $ | 569,795 | $ | 569,795 | ||||||||
(a)
|
Registrant’s principal executive and principal financial officers agree that Registrant’s disclosure controls and procedures, as defined in Rule 30a-3(c) under the 1940 Act, are effective, based on their evaluation of these controls and procedures, as required by Rule 30a-3(b), within 90 days of the filling date of this report.
|
(b)
|
During the Registrant’s last fiscal quarter, there were no changes in its internal controls over financial reporting that materially affected, or are likely to materially affect, the Registrant’s internal controls over financial reporting.
|
|
SIGNATURES
|
1.
|
I have reviewed this report on Form N-Q of Engex, Inc. (the “registrant”);
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the schedule of investments included in this report, fairly present in all material respects the investments of the registrant as of the end of the fiscal quarter for which the report is filed;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:
|
5.
|
The registrant’s other certifying officer and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of directors:
|
1.
|
I have reviewed this report on Form N-Q of Engex, Inc. (the “registrant”);
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the schedule of investments included in this report, fairly present in all material respects the investments of the registrant as of the end of the fiscal quarter for which the report is filed;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:
|
5.
|
The registrant’s other certifying officer and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of directors:
|
1 Year Engex Chart |
1 Month Engex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions